Illuminating Cellular and Molecular Pathways of Atherosclerosis Regression

Atherosclerosis, the clogging of arteries by deposits of fat and cholesterol, is a major cause of cardiovascular disease. Decades of basic scientific and clinical research have significantly clarified the pathways that lead to the deposition of fat in arteries and to the growth of atheroma. Although reducing the rate of atherosclerosis progression is desirable and has been achieved clinically by lipid lowering medication, an ideal treatment for atherosclerosis-related cardiovascular disease is to promote its regression. Our laboratory's primary research focus is the investigation of the less well understood and studied biology of atherosclerosis regression.

Recent Publications

Eberlé D, Kim RY, Luk FS, de Mochel NS, Gaudreault N, Olivas VR, Kumar N, Posada JM, Birkeland AC, Rapp JH, Raffai RL
Apolipoprotein E4 domain interaction accelerates diet-induced atherosclerosis in hypomorphic Arg-61 apoe mice.
Arteriosclerosis, thrombosis, and vascular biology, May-01-2012; 325: 1116-23.  Epub 2012 Mar 22.
Gaudreault N, Kumar N, Posada JM, Stephens KB, Reyes de Mochel NS, Eberlé D, Olivas VR, Kim RY, Harms MJ, Johnson S, Messina LM, Rapp JH, Raffai RL
ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium.
Arteriosclerosis, thrombosis, and vascular biology, Feb-01-2012; 322: 264-72.  Epub 2011 Nov 3.
Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, Raffai R
High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate.
American journal of physiology. Heart and circulatory physiology, Mar-01-2010; 2983: H1022-8.  Epub 2010 Jan 8.
Tie G, Yan J, Yang Y, Park BD, Messina JA, Raffai RL, Nowicki PT, Messina LM
Oxidized low-density lipoprotein induces apoptosis in endothelial progenitor cells by inactivating the phosphoinositide 3-kinase/Akt pathway.
Journal of vascular research, 476: 519-30.  Epub 2010 Apr 30.
Zhang S, Picard MH, Vasile E, Zhu Y, Raffai RL, Weisgraber KH, Krieger M
Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice.
Circulation, Jun-28-2005; 11125: 3457-64.  Epub 2005 Jun 20.
Raffai RL, Loeb SM, Weisgraber KH
Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.
Arteriosclerosis, thrombosis, and vascular biology, Feb-01-2005; 252: 436-41.
Raffaï RL, McPherson R, Weisgraber KH, Innerarity TL, Rassart E, Bersot TP, Milne RW
Antibody phenotyping test for the human apolipoprotein E2 isoform.
Clinical chemistry, Sep-01-2003; 499: 1524-6.
Raffai RL, Weisgraber KH
Cholesterol: from heart attacks to Alzheimer's disease.
Journal of lipid research, Aug-01-2003; 448: 1423-30.
Raffaï RL, Hasty AH, Wang Y, Mettler SE, Sanan DA, Linton MF, Fazio S, Weisgraber KH
Hepatocyte-derived ApoE is more effective than non-hepatocyte-derived ApoE in remnant lipoprotein clearance.
The Journal of biological chemistry, Mar-28-2003; 27813: 11670-5.
Raffai RL, Weisgraber KH
Hypomorphic apolipoprotein E mice: a new model of conditional gene repair to examine apolipoprotein E-mediated metabolism.
The Journal of biological chemistry, Mar-29-2002; 27713: 11064-8.
Raffai RL, Dong LM, Farese RV, Weisgraber KH
Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E.
Proceedings of the National Academy of Sciences of the United States of America, Sep-25-2001; 9820: 11587-91.
View all Publications »

News and Events

View all News»